Drugs / LY2590443
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00804973 | Nov 2008 → May 2009 | migraine disorder | Eli Lilly and Company | Terminated | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | LY2590443 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00804973 ↗ |
| Action | Inhibit | “Serotonin 7 (5-HT7) receptor antagonist” CHEMBL3545220 ↗ |
| Route | Oral | “200 milligrams (mg) as four 50-mg capsules, oral, once” NCT00804973 ↗ |
| Target | HTR7 | “Serotonin 7 (5-HT7) receptor antagonist” CHEMBL3545220 ↗ |